Insulin detemir

psilodex.org/m/insulin-detemir · data v2026.10.02

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Standard practice
Half-life: 5–7 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: insulin-detemir · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Basal insulin; hypoglycemia is the most common adverse reaction, and risk rises with light or skipped meals or nausea on session day. Low glucose impairs concentration and can be confused with, or intensify, session effects.

Human data with psilocybin: None known: no published human data with psilocybin
Half-life: 5–7 h terminal half-life (dose-dependent), duration of action longer (FDA label, checked 2026-10-02)

Evidence types on this record

PrStandard practice; no psilocybin-specific data

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Hypoglycemia risk: Can cause low blood sugar, especially if meals are missed or delayed. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Levemir (Insulin Detemir) Injection, Solution · FDA label (DailyMed) — 5.3 hypoglycemia; 17 patient counseling on symptoms

Record history

v2026.10.02First published.
2026-10-02Last reviewed against its sources.

Report an error in this record →